Business Wire

ABP-PUBLISHING

20.4.2021 11:02:09 CEST | Business Wire | Press release

Share
ABP Publishing Reports the Sales Increased 60% In 2020

The annual reports inform that the production and, thus, sales grew significantly whereas the audience preferences veered round into health and relations fields.

Besides, in 2021, the publishing house plans to acquire new genres in non-fiction and cooperate with new promising authors, retailers, and markets.

Although the circumstances made the editorial team work remotely, the number of published audiobooks did not diminish but increased. In particular, 109 books were recorded in 2020. The company published, among others, such bestsellers as Educated by Tara Westover, Flow by Mihaly Csikszentmihalyi, and Talking to Strangers by Malcolm Gladwell (German); Money. Master The Game by Tony Robbins, Bad Blood by John Carreyrou, and Big Magic by Elizabeth Gilbert (French); Atomic Habits by James Clear, Outliers by Malcolm Gladwell, and Becoming Supernatural by Joe Dispenza (Italian).

Additionally, in 2020, the publishing house started acquiring new languages producing books in Swedish, Turkish, Spanish, Norwegian, and Japanese.

The increase in production led to the rise in sales, logically. The sales report for 2020 showed a growth of 60 per cent, comparing to 2019. As mentioned, the listeners downloaded more books about health and relations, which is evidence of a slight change in audience preferences.

Further, in 2020, ABP Publishing worked on its ABP Verlag, ABP Editions, and ABP Editore brands. Every subsidiary got a new logotype and site. Moreover, each of the ABP Publishing books can be associated with the publisher, thanks to the standardised cover design.

Following the listeners' interests, in 2021, ABP Publishing plans to release audiobooks in fields and topics the company did not work with before, for instance, publicism and fiction. As an example, the German division has already published Demi Moore's autobiography while the French department is preparing the timeless classic bestseller Atlas Shrugged by Ayn Rand. Besides, the publisher increases the number of titles in relationship and parenting and popular science genres. It is important that despite the growing number of titles, the company keeps the high quality of audiobooks, practising an attentive approach to the voice-overs cast and music and dramatic audiobooks style.

Nevertheless, in the coming years, most publishers in the digital field will face the expansion of subscription and streaming model of distribution. The listeners appreciated the profit of the unlimited access to audiobooks, whereas the publishing houses are switching to a new reality reluctantly. Anyway, all the publishing companies will have to find a balance between listeners' wishes and desirable income. ABP Publishing believes that the changes will be advantageous for all the market participants and cause the better quality of published audiobooks in competitive terms.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release

Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me

BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release

Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye